secondary amyloidosis


Also found in: Dictionary, Thesaurus, Encyclopedia.
Related to secondary amyloidosis: primary amyloidosis, AA amyloidosis

sec·on·dar·y am·y·loi·do·sis

amyloidosis occurring in association with another chronic inflammatory disease; organs chiefly involved are the liver, spleen, and kidneys, and the adrenal glands less frequently.

secondary amyloidosis

sec·on·dar·y am·y·loid·o·sis

(sek'ŏn-dar-ē am'i-loy-dō'sis)
Amyloidosis occurring in association with another chronic inflammatory disease; organs chiefly involved are the liver, spleen, and kidneys; the suprarenal glands less frequently.

sec·on·dary am·y·loid·o·sis

(sek'ŏn-dar-ē am'i-loy-dō'sis)
Amyloidosis occurring in association with another chronic inflammatory disease; organs chiefly involved are the liver, spleen, and kidneys.

amyloidosis

the deposition in various tissues of amyloid. This protein is almost insoluble and once it infiltrates the tissues they become waxy and nonfunctioning. Systemic amyloidosis may be immunocytic or reactive (see below).

cutaneous amyloidosis
multiple cutaneous, hard, painless, chronic plaques occur over the head, neck and shoulders of horses. There may be involvement of the nasal mucosa and resulting dyspnea.
familial renal amyloidosis of Shar pei dogs
manifested by episodic fever and swelling of one or both hocks which may resolve spontaneously, but is recurring. The condition is resistant to treatment and eventually there is renal and/or hepatic failure.
immunocytic amyloidosis, immunogenic amyloidosis, primary amyloidosis
amyloid produced from light chains of immunoglobulins as in plasma-cell dyscrasias. See also al protein.
reactive amyloidosis
is derived from excess serum protein SAA produced as a result of chronic antigenic stimulation. The kidney is most often affected and the amyloid is most often deposited in glomeruli but medullary deposits are seen in cats and cattle. Idiopathic amyloidosis is common in the dog and less common in cats. It is associated with chronic suppurative disease processes in cattle, antiserum production in horses, and it occurs rarely in pigs. Called also secondary alopecia.
renal amyloidosis
characterized by severe proteinuria and uremia. There is chronic diarrhea, polydipsia and anasarca. Seen particularly in dogs and cats.
secondary amyloidosis
reactive amyloidosis (above).
References in periodicals archive ?
4) The prognosis of FMF with the development of secondary amyloidosis is often good but depends on the severity of any damage resulting from amyloidosis and if treatment has been appropriately provided.
Neurochem's most advanced product candidate is Fibrillex(TM), in pivotal Phase II/III clinical development for the treatment of Secondary Amyloidosis, a fatal kidney disease.
3) Thus, a lack of awareness of a population for FMF would lead to an increased rate of secondary amyloidosis.
The study will evaluate the efficacy and safety of the orally active anti-amyloid treatment, Fibrillex(TM), in patients suffering from Secondary Amyloidosis," said Dr.
The amyloid deposits found in Secondary Amyloidosis are associated with certain inflammatory conditions including rheumatoid arthritis and Crohn's Disease.
Neurochem's research and clinical teams are best known for their development of therapeutic and diagnostic drug candidates for amyloid-related diseases, including Alzheimer's Disease, Secondary Amyloidosis, Diabetes Type II and Hemorrhagic Stroke (due to Cerebral Amyloid Angiopathy).
The Company also received Orphan Medicinal Product (OMP) designation in Europe for its lead drug candidate, Fibrillex(TM), for the treatment of Secondary Amyloidosis.
Neurochem has advanced three drug candidates to clinical trials for Alzheimer's Disease, Secondary Amyloidosis and Hemorrhagic Stroke.
Secondary Amyloidosis is a potentially fatal disease associated with chronic infection or chronic inflammatory diseases in which amyloid fibrils deposit in tissues and organs, impairing their function.
TSE : NRM) has received approval from the Clinical Trials Unit of the Medicines Control Agency in the United Kingdom for the initiation of a pivotal Phase II/III clinical study for Fibrillex(TM), an anti-amyloid drug expected to treat patients suffering from Secondary Amyloidosis.